Acoramidis Hydrochloride
A transthyretin (TTR) stabilizer. By stabilizing transthyretin (TTR) and inhibiting its misfolding and amyloid deposition, it is used to treat transthyretin amyloid cardiomyopathy (ATTR-CM).
Overview
Acoramidis hydrochloride is an effective transthyretin (TTR) stabilizer, a small - molecule agent that acts by stabilizing transthyretin and inhibiting its misfolding as well as amyloid deposition, thus exerting therapeutic effects on transthyretin amyloidosis - related diseases. Acoramidis Hydrochloride can be used in the research of transthyretin amyloid cardiomyopathy (ATTR - CM) and other relevant conditions to explore disease progression mechanisms and therapeutic strategies.
Synonyms: BBP-265; AG-10; ALXN-2060; ALXN 2060; Attruby; Beyonttra; Eidos Therapeutics AG10; AG10 hydrochloride; 3-(3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid HCl; Acoramidis hydrochloride; AG10 hydrochloride; 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid hydrochloride; Acoramidis?hydrochloride?(AG10 hydrochloride); Acoramidis hydrochloride, 10 mM in DMSO
Product Categories: Acids, Carbocyclic; BCRP/ABCG2 Substrates; Cardiac Therapy; Cytochrome P-450 CYP2C9 Inhibitors; Transthyretin Stabilizers
Mol File: 2242751-53-5.mol
Physicochemical Properties
Solubility: DMSO: Sparingly Soluble: 1-10 mg/mL
Form: Solid
Color: White to Light Yellow
MSDS Information
Experimental Data
1. Cell Experiment
Solubility in DMSO : 62.5 mg/mL (190.10 mM; ultrasonic co-solubilization; Hygroscopic DMSO has a significant effect on the solubility of the product, use freshly opened DMSO);H2Solubility in O : < 0.1 mg/mL (insoluble).
Preparing Stock Solutions:

Please choose the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; Once prepared into a solution, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and duration of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。 Use within 6 months when stored at -80°C, and within 1 month when stored at -20°C.
2. Animal Control
Choose the appropriate dissolution protocol based on your experimental animal and mode of administration.For the following dissolution schemes, please prepare the clarified stock solution according to the in vitro method, and then add the co-solvent in turn:
- In order to ensure the reliability of the experimental results, the clarified stock solution can be properly stored according to the storage conditions; It is recommended that you use the working solution for in vivo experiments and use it on the same day;The percentages shown before the following solvents are the proportion of the volume of that solvent in your final solution; If precipitation and precipitation occur during the preparation process, it can be dissolved by heating and/or ultrasound.
Option 1
Add each solvent in order:10% DMSO,40% PEG300, 5% Tween-80, 45% Saline
Solubility: ≥ 2.08 mg/mL (6.33 mM); Clear solution
A clarified solution of ≥ 2.08 mg/mL (saturation unknown) is obtained for this protocol.
For example, take 1 mL of working solution and add 100 μL of 20.8 mg/mL of clarified DMSO stock solution to 400 μL of PEG300 and mix well. Add 50 μL of Tween-80 to the above system and mix well; Then proceed with 450 μL of normal saline to 1 mL.
Preparation of normal saline: 0.9 g of sodium chloride dissolved in ddH₂O and fixed to 100 mL can obtain a clear and transparent normal saline solution.
Option 2
add each solvent in order: 10% DMSO,90% (20% SBE-β-CD in Saline)
Solubility:≥ 2.08 mg/mL (6.33 mM);Clear solution
A clarified solution of ≥ 2.08 mg/mL (saturation unknown) is obtained for this protocol.
For example, 100 μL of 20.8 mg/mL of clarified DMSO stock solution is added to 900 μL of 20% SBE-β-CD saline in water and mixed well.
2 g of SBE-β-CD (sulfonbutyl ether β-cyclodextrin) powder is set in 10 mL of normal saline and completely dissolved until clear.
Option 3
add each solvent in order: 10% DMSO,90% Corn Oil
Solubility:≥ 2.08 mg/mL (6.33 mM);Clear solution
A clarified solution of ≥ 2.08 mg/mL (saturation unknown) is available for use in animal experiments with an experimental period of more than half a month, as appropriate.
For example, 100 μL of 20.8 mg/mL of clarified DMSO stock solution was added to 900 μL of corn oil and mixed well.
Pharmacodynamics
Mechanism Of Action
Similar Products

Glycerol Phenylbutyrate
Therapy
: Orphan diseases
Target
: Sigma Receptor
CAS
: 611168-24-2
MF
: C33H38O6
MW
: 530.65

Ivacaftor
Therapy
: Orphan diseases
Target
: CFTR
CAS
: 873054-44-5
MF
: C24H28N2O3
MW
: 392.49

Migalastat Hydrochloride
Therapy
: Orphan diseases
Target
: α-Gal A
CAS
: 75172-81-5
MF
: C6H13NO4.ClH
MW
: 199.63

AFICAMTEN
Therapy
: Orphan diseases
Target
: Cardiac myosin
CAS
: 2364554-48-1
MF
: C18H19N5O2
MW
: 337.38
